These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 18488219)

  • 21. Cancer vaccines: translation from mice to human clinical trials.
    Maeng H; Terabe M; Berzofsky JA
    Curr Opin Immunol; 2018 Apr; 51():111-122. PubMed ID: 29554495
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dendritic cells in cancer immunotherapy.
    Vulink A; Radford KJ; Melief C; Hart DN
    Adv Cancer Res; 2008; 99():363-407. PubMed ID: 18037410
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Current status and future perspectives of dendritic cell-based cancer immunotherapy.
    H Yi D; Appel S
    Scand J Immunol; 2013 Aug; 78(2):167-71. PubMed ID: 23672402
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Anticancer immunotherapy in combination with proapoptotic therapy.
    Bruserud Ø; Ersvaer E; Olsnes A; Gjertsen BT
    Curr Cancer Drug Targets; 2008 Dec; 8(8):666-75. PubMed ID: 19075589
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Combining targeted therapy with immunotherapy. Can 1+1 equal more than 2?
    Robert L; Ribas A; Hu-Lieskovan S
    Semin Immunol; 2016 Feb; 28(1):73-80. PubMed ID: 26861544
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Drug Delivery for Cancer Immunotherapy and Vaccines.
    Batty CJ; Tiet P; Bachelder EM; Ainslie KM
    Pharm Nanotechnol; 2018; 6(4):232-244. PubMed ID: 30227827
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Novel mechanism of synergistic effects of conventional chemotherapy and immune therapy of cancer.
    Ramakrishnan R; Gabrilovich DI
    Cancer Immunol Immunother; 2013 Mar; 62(3):405-10. PubMed ID: 23423351
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [New directions in immunotherapy for malignant solid tumors].
    Okuno K; Sugiura F; Sukegawa Y; Inoue K
    Nihon Rinsho; 2012 Dec; 70(12):2075-86. PubMed ID: 23259377
    [TBL] [Abstract][Full Text] [Related]  

  • 29. NY-ESO-1 Based Immunotherapy of Cancer: Current Perspectives.
    Thomas R; Al-Khadairi G; Roelands J; Hendrickx W; Dermime S; Bedognetti D; Decock J
    Front Immunol; 2018; 9():947. PubMed ID: 29770138
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tumor Plasticity and Resistance to Immunotherapy.
    Horn LA; Fousek K; Palena C
    Trends Cancer; 2020 May; 6(5):432-441. PubMed ID: 32348738
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combination of active specific immunotherapy or adoptive antibody or lymphocyte immunotherapy with chemotherapy in the treatment of cancer.
    Zhang T; Herlyn D
    Cancer Immunol Immunother; 2009 Apr; 58(4):475-92. PubMed ID: 18925393
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacological combination of nivolumab with dendritic cell vaccines in cancer immunotherapy: An overview.
    Calmeiro J; Carrascal MA; Tavares AR; Ferreira DA; Gomes C; Cruz MT; Falcão A; Neves BM
    Pharmacol Res; 2021 Feb; 164():105309. PubMed ID: 33212291
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Does chemotherapy augment anti-tumor immunotherapy by preferential impairment of regulatory T cells?
    Zhang L; Dermawan KT; Jin ML; Xiong SD; Chu YW
    Med Hypotheses; 2008 Nov; 71(5):802-4. PubMed ID: 18691831
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Considerations for the combination of anticancer vaccines and immune checkpoint inhibitors.
    Strauss J; Madan RA; Gulley JL
    Expert Opin Biol Ther; 2016 Jul; 16(7):895-901. PubMed ID: 27010190
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Targeting the immune system in the treatment of non-small-cell lung cancer.
    Rangachari D; Brahmer JR
    Curr Treat Options Oncol; 2013 Dec; 14(4):580-94. PubMed ID: 23934510
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunomodulatory effects of current cancer treatment and the consequences for follow-up immunotherapeutics.
    Mooradian MJ; Sullivan RJ
    Future Oncol; 2017 Aug; 13(18):1649-1663. PubMed ID: 28776423
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunotherapy: cancer immunotherapy and its combination with nanomaterials and other therapies.
    Guo Y; Gao F; Ahmed A; Rafiq M; Yu B; Cong H; Shen Y
    J Mater Chem B; 2023 Sep; 11(36):8586-8604. PubMed ID: 37614168
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Recent Advances in Cancer Stem Cell Targeted Therapy.
    Akbulut H; Babahan C; Abgarmi SA; Ocal M; Besler M
    Crit Rev Oncog; 2019; 24(1):1-20. PubMed ID: 31679215
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Therapeutic Cancer Vaccines.
    Ye Z; Li Z; Jin H; Qian Q
    Adv Exp Med Biol; 2016; 909():139-67. PubMed ID: 27240458
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Regulators of apoptosis: suitable targets for immune therapy of cancer.
    Andersen MH; Becker JC; Straten Pt
    Nat Rev Drug Discov; 2005 May; 4(5):399-409. PubMed ID: 15864269
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.